• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

8 de June de 2021
Future Oncol. 2021 Sep;17(25):3291-3299. doi: 10.2217/fon-2020-1133.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-06-08 10:00:002021-06-08 10:00:00KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool

25 de May de 2021
Sci Rep. 2021 May 24;11(1):10780. doi: 10.1038/s41598-021-89927-5.ABSTRACTLack…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-05-25 10:00:002021-05-25 10:00:00Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool

Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes

30 de April de 2021
J Pers Med. 2021 Apr 22;11(5):331. doi: 10.3390/jpm11050331.ABSTRACTEctonucleoside…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-04-30 10:00:002021-04-30 10:00:00Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes

Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression

3 de April de 2021
Int J Mol Sci. 2021 Mar 6;22(5):2669. doi: 10.3390/ijms22052669.ABSTRACTUveal…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-04-03 10:00:002021-04-03 10:00:00Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression

Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11

6 de March de 2021
J Control Release. 2021 Apr 10;332:517-528. doi: 10.1016/j.jconrel.2021.02.035.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-03-06 11:00:002021-03-06 11:00:00Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11

Codon Usage and Adenovirus Fitness: Implications for Vaccine Development

1 de March de 2021
Front Microbiol. 2021 Feb 10;12:633946. doi: 10.3389/fmicb.2021.633946.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-03-01 11:00:002021-03-01 11:00:00Codon Usage and Adenovirus Fitness: Implications for Vaccine Development

Survival in small choroidal melanocytic lesions with risk factors managed by initial observation until detection of tumour growth

26 de February de 2021
Clin Exp Ophthalmol. 2021 Apr;49(3):251-259. doi: 10.1111/ceo.13911.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-02-26 11:00:002021-02-26 11:00:00Survival in small choroidal melanocytic lesions with risk factors managed by initial observation until detection of tumour growth

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

12 de February de 2021
Eur J Cancer. 2021 Mar;146:30-47. doi: 10.1016/j.ejca.2020.12.023.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-02-12 11:00:002021-02-12 11:00:00Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

Mesenchymal stem cells and oncolytic viruses: joining forces against cancer

9 de February de 2021
J Immunother Cancer. 2021 Feb;9(2):e001684. doi: 10.1136/jitc-2020-001684.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-02-09 11:00:002021-02-09 11:00:00Mesenchymal stem cells and oncolytic viruses: joining forces against cancer

Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus

2 de February de 2021
Clin Cancer Res. 2021 Jun 1;27(11):2979-2988. doi: 10.1158/1078-0432.CCR-20-1565.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-02-02 11:00:002021-02-02 11:00:00Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus

Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

8 de January de 2021
J Clin Oncol. 2021 Feb 20;39(6):586-598. doi: 10.1200/JCO.20.00550.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-01-08 11:00:002021-01-08 11:00:00Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma

2 de December de 2020
Clin Cancer Res. 2021 Mar 1;27(5):1491-1504. doi: 10.1158/1078-0432.CCR-20-0232.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2020-12-02 11:00:002020-12-02 11:00:00FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
Page 7 of 11«‹56789›»

Filter by categories

  • Alemany’s & Piulats’s lab (131)
  • Antolin's lab (36)
  • Aytes's Lab (24)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sureda's & Farre's Lab (259)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}